Trial Profile
Efficacy of Osimertinib in patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) with pleural effusion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2018
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jun 2018 New trial record
- 01 Jun 2018 Results published in the Anticancer Research